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Abstract
Background: Osteogenesis imperfecta (OI) covers a spectrum of bone fragility disorders. OI is classified into five
types; however, the genetic causes of OI might hide in pathogenic variants of 20 different genes. Often clinical OI
types mimic each other. This sometimes makes it impossible to identify the OI type clinically, which can be a risk
for patients. Up to 90% of OI types I–IV are caused by pathogenic variants in the COL1A1/2 genes. OI type V is
caused by the c.-14C > T pathogenic variant in the 5′UTR of the IFITM5 gene and is characterized by hyperplastic
callus formation and the ossification of interosseous membranes.
Results: In the current study, we performed IFITM5 5′UTR region mutational analysis using Sanger sequencing on
90 patients who were negative for COL1A1/2 pathogenic variants. We also investigated the phenotypes of five
patients with genetically confirmed OI type V. The proportion of OI type V patients in our cohort of all OI patients
was 1.48%. In one family, there was a history of OI in at least three generations. Phenotype severity differed from
mild to extremely severe among patients, but all patients harbored the same typical pathogenic variant. One
patient had no visible symptoms of OI type V and was suspected to have had OI type IV previously. We also
identified a case of extremely severe hyperplastic callus in a 15-year-old male, who has hearing loss and brittleness
of teeth.
Conclusions: OI type V is underlined with some unique clinical features; however, not all patients develop them.
The phenotype spectrum might be even broader than previously suspected, including typical OI features: teeth
brittleness, bluish sclera, hearing loss, long bones deformities, and joint laxity. We suggest that all patients negative
for COL1A1/2 pathogenic variants be tested for the presence of an IFITM5 pathogenic variant, even if they are not
expressing typical OI type V symptoms. Further studies on the pathological nature and hyperplastic callus formation
mechanisms of OI type V are necessary.
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Background
Osteogenesis imperfecta (OI) covers a spectrum of rare,
genetic connective tissue disorders, outlined by bone fra-
gility, skeletal deformations, and recurrent fractures [1].
Typical symptoms of OI include blue sclera, dentinogen-
esis imperfecta (DI), hearing loss, and joint laxity [2–4].
The genetic spectrum of OI is composed of 20 different
OI genes [5–7]. Up to 90% of OI cases arise from the het-
erozygous pathogenic variants of the COL1A1 (OMIM
120150) and COL1A2 (OMIM 120160) genes, which code
for collagen type I α1, 2 chains [8]. One more gene repre-
senting autosomal dominant OI is the IFITM5 (OMIM
610967) gene, which codes for a bone-restricted ifitm-like
protein (BRIL) [9]. Up to 5% of individuals from OI popu-
lation harbor pathogenic variants in the IFITM5 gene
[10]. The remaining OI cases are caused by pathogenic
variants in the recessive OI genes [7, 11–23].
Genetic heterogeneity is reflected in the broad variabil-
ity of OI phenotypes. In 1979, David Sillence classified
OI based on the clinical severity as follows: type I—non-
deforming OI with blue sclera; type II—lethal OI; type
III—severe deforming OI; and type IV—variable OI
without blue sclera [4]. In 2000, based on histological
and radiological evidences, Glorieux et al. proposed the
existence of an additional variant, OI type V [24]. This
particular OI type differed due to its mesh-like pattern
of lamellation, hyperplastic callus (HPC) formation, and
calcification of the interosseous membrane in the fore-
arm [24–26]. Patients with OI type V are described to
mimic symptoms of OI type IV with moderate severity
of long-bone deformities, vertebral compression frac-
tures, scoliosis, and the same number of fractures. How-
ever, unlike type IV, patients with OI type V were
claimed not to develop DI or blue sclera [25].
Recent studies have introduced variability in the OI
type V phenotypes [25, 27–30]. The spectrum of OI type
V phenotypes has been expanded with phenotypes mim-
icking OI type I and III and [31]. Despite phenotype var-
iations, all patients with OI type V harbor the same
genetic change—a pathogenic variant in the 5′ untrans-
lated (UTR) region of the IFITM5 gene, c.-14C > T [32,
33].
Neither the physiological function of the IFITM5 gene
product, BRIL protein, nor the effect of the mutated pro-
tein is fully understood. As it is known, c.-14C > T substi-
tution in the 5′UTR region of the IFITM5 gene creates a
new upstream start codon and causes the inclusion of five
additional amino acids to the N-termini of the BRIL pro-
tein (MALEP) [34]. However, the exact pathological
mechanism of OI type V remains unclear; it was hypothe-
sized that the MALEP-IFITM5 acts in a neomorphic man-
ner, gaining a new molecular function [35].
Despite the genetic cause of OI type V first being pub-
lished in 2012, the discovery of patients harboring the
c.-14C > T IFITM5 variant is still rare, and many of them
do not develop traits characteristic of OI type V [31–33].
Thus, the description of phenotypes in patients of OI
type V is of particular interest, as it enriches our under-
standing of phenotypical variability and approaches to
the diagnosis of OI type V.
In this study, we have screened for the presence of a
c.-14C > T IFITM5 pathogenic variant in a cohort of 90
unrelated Estonian, Ukrainian, and Vietnamese OI pa-
tients negative for collagen type I pathogenic variants
with diverse OI phenotypes. Herein, we report the
phenotypical characteristics captured during the screen-
ing of five OI type V patients with identical c.-14C > T
pathogenic variants in the IFITM5 gene and phenotypes
of different severity. Also, for the first time, we report a
case of an OI type V patient with extremely severe callus
and hearing loss.
The management and diagnosis of OI is performed by
clinical geneticists. OI type V is one of the rarest OI
types, as such, is often misdiagnosed. We believe that
sharing the data from patients with rare OI types is an
important contribution to the field. In many countries,
not all patients undergo genetic testing and OI is often
diagnosed based on phenotypical features. This article il-
lustrates the high degree of variation in the clinical
symptoms of OI type V. Additionally, it highlights the
critical importance of identifying the specific variant at
hand to develop an appropriate treatment strategy and
counseling for family planning.
Materials and methods
The study was performed using patients from the OI bio-
bank of the Clinic of Traumatology and Orthopedics from
the University of Tartu, Estonia (UT OI biobank). The UT
OI biobank consists of 237 OI families from Estonia,
Ukraine, and Vietnam, including 337 samples from OI af-
fected individuals and their healthy relatives. Informed
written consent was collected from all subjects and con-
trols, or their legal representatives, prior to their participa-
tion in the study. The study was conducted in accordance
with the Helsinki Declaration and authorized by the Eth-
ical Review Committee on Human Research of the Uni-
versity of Tartu (Permit no. 221/M-34), the Ethical Review
Board of Hue University Hospital (approval No. 75/CN-
BVYD), and the Sytenko Institute of Spine and Joint Path-
ology of the Ukrainian Academy of Medical Sciences. De-
tails of the patient recruitment process are described
elsewhere. [36–38]
For the current study, we used a cohort of 90 unre-
lated OI patients negative for COL1A1/2 pathogenic var-
iants. Patients were previously diagnosed with OI of
different severity (Sillence classification, types I–IV)
based on clinical features. Only one patient was sus-
pected to have OI type V due to significant, visible HPC.
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To capture a typical pathogenic variant causing OI
type V, a cohort of selected patients were screened for
the presence of a c.-14C > T pathogenic variant in the
IFITM5 gene. Focusing on the mutational analysis of the
specific locus, we have selected Sanger sequencing of the
5′UTR region of the IFITM5 gene to be the most accur-
ate approach to meet the needs of this study. Genomic
DNA extraction was performed from the ethylenedi-
aminetetraacetic acid (EDTA)-preserved blood samples
using the Gentra Puregene Blood Kit (QIAGEN,
Germany) according to the manufacturer’s protocol and
stored at − 80 °C.
DNA samples were amplified using a PCR with a spe-
cially designed primer pair covering the 5′UTR region
and exon 1 of the IFITM5 gene.
The PCR reaction was performed with 5x HOT FIRE-
Pol® Blend Master Mix Ready to Load (Solis BioDyne,
Estonia). PCR reaction was performed with a Thermal
Cycler (Applied Biosystems, USA) PCR machine. Add-
itional details on the PCR procedures are available from
the authors upon reasonable request.
Amplified PCR products were electrophoresed
through a 1.5% agarose gel. PCR products were purified
with Exonuclease I and Shrimp Alkaline Phosphatase
(Thermo Fisher Scientific, USA). Sanger sequencing re-
actions were performed from purified PCR fragments
using BigDye® Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, USA). Reactions were processed
on the ABI3730xl instrument.
Sequence reads were analyzed with Sequence Scanner
v1.0 of Applied Biosystems and aligned to the RefSeq se-
quence NM_001025295.1. Sequence analysis and patho-
genic variant identification was performed with Mutation
Surveyor DNA variant analysis software (Softgenetics,
USA). Presence of a c.-14C > T variant was controlled in a
screened cohort. Predictions for the pathogenicity and
functional impact of the 5′UTR variants were provided
with Mutation Taster. All analyses were conducted at the
University of Tartu (Estonia). Sequencing data is available
from the authors upon reasonable request.
Results
Results of mutational analysis
According to clinical diagnosis, out of the 90 unrelated OI
patients screened, OI was suspected only in one case
(1.11%). However, after screening of the 90 unrelated pa-
tients, we have identified four patients (4.44%) harboring a
heterozygous c.-14C > T variant in the 5′UTR region of
the IFITM5 gene. Three patients came from the Ukrainian
OI cohort. One patient came from Vietnamese cohort.
There were no patients with OI type V among the Esto-
nian OI population. Parents of three affected patients did
not harbor pathogenic variants, which confirmed the de
novo nature of the pathogenic variant. Only one patient
had a family history of OI, whose mother was a carrier of
a c.-14C > T heterozygous variant in the IFITM5 gene
also. The overall prevalence of OI type V in the UT OI
biobank was 5/337 (1.48%) (Table 1).
HPC and radial head dislocation was identified in 4/5
patients. Interosseous membrane calcification and meta-
physeal radiodense bands were observed in 3/5 cases.
Three patients had bluish and two had grayish eye sclera.
There were no registered cases of DI among our patients.
However, patient 1 developed teeth brittleness of an un-
known nature. Patient 1 had also developed hearing loss,
which started at the age of 14. Both patients 2 and 3,
which came from family with a history of OI, had joint
laxity. The overall number of fractures in patients 1–5
ranged from 0.5 to 2.3 per year. Patients developed mostly
mild deformity of their long bones in both their upper and
lower extremities. Scoliosis and chest deformity was found
in 3/5 patients. Only one patient was immobile. According
to their height Z scores, the patients are shorter than aver-
age in the age and sex-matched group. Growth retardation
seemed to be greater with age (Table 1). Detailed descrip-
tions of the patients’ cases are represented below.
Patient 1
Patient 1 is a 15-year-old male (lock time September 2017)
and the only child of a healthy non-consanguineous
Ukrainian family (family 1) (Fig. 1b). His mother had her
first pregnancy without a history of miscarriages. The preg-
nancy was full term without any health concerns. The pa-
tient’s birth weight was 3.5 kg (Z score − 0.06, 48% centile),
his birth length was 52 cm (Z score 0.76, 78% centile), and
he was in good condition immediately after birth. The pa-
tient’s current weight is 45 kg (Z score − 1.32, 9% centile)
with a height of 135 cm (Z score − 3.93, 0% centile). The
patient has grayish eye sclera, brittleness of teeth, and hear-
ing loss, which started at the age of 14. The patient suffers
from headaches, urolithiasis, and pyelonephritis.
The total number of fractures was eight. Patient 1 suf-
fered his first fracture at the age of 1 year and 3 months in
the right hip. The next fracture happened in the jaw, at
the age of four, due to a fall. At the age of seven, the pa-
tient fractured his lower left leg. At the age of eight, the
patient re-fractured their lower left leg along with fractur-
ing their left arm. At the age of nine, the patient had re-
ceived a blow to their hip, and within a month the patient
had developed an irregular-shaped crack of the cortex
where the blow had been dealt. The patient had equal
thickening of the cortex on both side femurs. Within 2-
months, a sarcoma-like ossification was discovered, sized
5 × 4 cm, without a clear contour line. After 1.5 months,
the ossification enlarged to 7 × 5 cm with some thickening
and a clearer contour line. In 2017, hyperplastic callus for-
mation was extreme (Fig. 1c). The lower limb developed
inflammatory symptoms: redness, fever, and enlarged in
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size (Fig. 1a). Patient 1 was diagnosed with pseudo osteo-
sarcoma. Patient 1 underwent osteosynthesis. After a few
months, the patient suffered a right hip fracture and
underwent osteosynthesis of his right femur.
The patient developed deformation of the spine and com-
bined deformities of his lower, upper limbs, and chest. The
patient has HPC of the right humerus and both femurs
(Fig. 1c), congenital synostosis of the right forearm (radioul-
nar interosseous membrane calcification), and contracture
of his right elbow joint (radial head dislocation) (Fig. 1c).
The patient suffers from severe HPC formation in the hips
(from 2011, age 9). Due to severe callus, the patient is im-
mobile and unable to sit (Fig. 1c). The bone mineral density
(BMD) Z-score of the spine was − 5.9 and the lower arm
received a Z-score BMD of − 3.6. The patient underwent
bisphosphonate treatment with pamidronate.
Results of histological bone biopsy analysis showed that
his callus bone tissue is immature and hypercellular. The
patient’s new grown bone trabeculae have a high number
of osteoblasts located at the basophil intercellular matter,
with the inclusion of cartilage regions. Both the patient’s
osteoblasts and osteocytes do not show any abnormalities.
On the contour line, there is quite a significant number of
osteoclasts. The intertrabecular space is filled with numer-
ous blood vessels and fibroreticular tissue. The blood ves-
sels are sinusoidal with large wide pores. The patient’s
bone marrow is hypocellular and hydropic with regions
with hemorrhagic infiltration.
Patient 2
Patient 2 is a 4-year-old boy (lock time May 2016) from a
Ukrainian family with three generations of OI history
from the mother’s line (family 2) (Fig. 2a). The mother
had a healthy full-term pregnancy, without any previous
miscarriages. His birthweight was 2.5 kg (Z score − 1.68,
5% centile), and his birth length was 51 cm (Z score 0.38,
65% centile). There were no signs of deformities or frac-
tures after delivery.
The patient’s first fracture appeared at the age of 7 months
in the femur during massage. At 8 and 11 months, the
Table 1 Phenotype characteristics of OI type V patients
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age 15 4 34 7 5
Sex m m f f f
Country Ukraine Ukraine Ukraine Ukraine Vietnam
Phenotype Severe Mild Moderate Moderate Mild
Mimicking classic OI type V I IV IV I
OI history in the family No Yes Yes No No
Hyperplastic callus Yes, extreme Yes Yes No Yes
Interosseous membrane calcification Yes Yes Yes (fibula-tibia) No No
Radial head dislocation Yes Yes Yes No Yes
Metaphyseal radiodense band NA Yes Yes No Yes
Hearing loss Yes, age 14 No No No No
Dentinogenesis imperfecta No, teeth brittle No No No
Sclera hue Grayish Bluish Bluish Grayish Bluish
Number of fractures 8 4 26 16 5
Number of fractures per year 0.5 1 0.8 2.3 1
Time of the first fracture 1.3 7 months at birth 3 months 2
First fractured bone Femur Left femur Elbow, femur Scapula Lower leg
The most frequently fractured bone Femur Femur Femur Legs Lower leg
Pyramidal/bell-shaped chest Yes, severe No Yes Yes No
Scoliosis Yes No Yes Yes No
Upper limb long bone deformity Yes, mild Yes, mild Yes No Yes, mild
Lower limb long bone deformity Yes Yes, mild Yes Yes, mild Yes, mild
Mobility Immobile, lying Walking Walking (did not walk at age 9–14) Walking Walking
Height (Z score) − 3.93 0.66 − 2.70 − 2.83 − 1.22
Birthweight and length 52/3450 51/2500 52/3300 50/2800 NA/2800
Joint laxity No Yes Yes No NA
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Fig. 1 Patient 1. a Hyperplastic callus formation in the femur. b Genealogical tree of patient 1 (family 1). c Radiological features of patient 1
Fig. 2 Patient 2. a Genealogical tree of patients 2 and 3 (family 2). b Radiological features of patient 2
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patient fractured both their right and left femur. After-
wards, the patient followed treatment with pamidronate.
The last fracture happened at the age of 4, in the left fore-
arm. The total number of fractures was 4.
The patient’s current weight is 15 kg (Z score − 0.68,
25% centile) and their height is 105 cm (Z score 0.66,
74% centile). The patient has bluish eye sclera and joint
laxity. He is active and able to move independently.
Signs of DI and hearing loss are absent.
Patient 2 has mild phenotype, mild deformities of chest,
long lower and upper limb bones, with radial head dis-
location and radioulnar interosseous membrane calcifica-
tion (Fig. 2c). Investigation of X-rays showed the presence
of HPC and a metaphyseal radiodense band (Fig. 2c).
Patient 3
Patient 3 is a 34-year-old female from Ukraine (lock time
May 2016) and the mother of patient 2 (family 2) (Fig. 2a).
Her birthweight was 3.3 kg (Z score − 0.2, 42% centile),
and her birth length was 52 cm (Z score 1.0, 85% centile).
During being born, she had numerous fractures: both
elbow, left hip, and both lower legs. The total number of
fractures was 26. The majority of the fractures affected the
lower limbs, especially the femur. She became immobile
between the ages of 9 and 14.
At the age of 9, the lower and upper limbs developed
HPC. She also has calcification of the interosseous mem-
brane in the fibula and tibia along with radial head dis-
location. An investigation of X-rays revealed the presence
of a metaphyseal radiodense band. The patient had chest
deformation, scoliosis, and deformities of the long bones
in both upper and lower limbs (Fig. 3a). The patient cur-
rently walks independently. The patient has moderate
phenotype, mimicking OI type IV, no DI, or hearing loss.
Her eye sclera is bluish. The patient has joint laxity. Her
current weight is 42 kg and her height is 145 cm (Z score
− 2.70, 0% centile).
Patient 4
Patient 4 is a 7-year-old girl from Ukraine (lock time May
2016). The patient has moderate OI phenotype, mimicking
OI type IV without any visible features of OI type V. The
patient was initially misdiagnosed with OI type IV. Patient
4 has no family history of OI (family 3) (Fig. 4a). Her
birthweight was 2.8 kg (Z score − 1.18, 12% centile), and
her birth length was 50 cm (Z score 0.28, 61% centile).
There were no deformities or fractures during delivery;
Fig. 3 Patient 3. a Radiological features of patient 3
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however, she had an unmineralized skull. At the age of
3 months, the first fracture appeared in the scapula during
massage. The total number of fractures is 16. Most frac-
tures affected the lower limbs. The patient’s left lower leg
was fractured ten times. She had osteosynthesis on left
lower and upper leg (Fig. 4b). The patient follows treat-
ment with pamidronate. She has some deformities of
lower limbs, spine, and chest (Fig. 4b). The patient had no
hearing loss, DI, or joint laxity. Her eye sclera are gray.
Her current weight is 17 kg (Z score − 2.22, 1% centile)
and her height is 107 cm (Z score − 2.83, 0% centile). The
patient is active and able to walk independently. Typical
characteristics of OI type V, like HPC, interosseous mem-
brane calcification, radial head dislocation, and a metaphy-
seal radiodense band, are absent.
Patient 5
Patient 5 is a 7-year-old girl from Vietnam, with mild OI
phenotype (lock time 2015). Her father suffered some
fractures in his forearms when he was under 10 years old.
We do not have additional evidence of fractures in any of
the other family members (family 4). An absence of con-
sanguineous marriage was also confirmed (Fig. 5a). The
mother had full-term pregnancy with 40 weeks of gesta-
tion, good health, and no history of miscarriages. Her
birthweight was 2.8 kg (Z score − 1.18, 12% centile).
Current clinical examination showed a weight 19 kg (Z
score − 1.27, 10% centile) and height 115 cm (Z score −
1.22, 11% centile). She has blue sclera.
The patient suffered her first fracture at the age of 2 years
old. The patient had five fractures on both side tibias. Mild
deformities appeared in the long bones of the forearms
and lower legs (Fig. 5b). She is able to move normally. The
patient did not follow bisphosphonate treatment. On the
radiological examination, ossifications of the interosseous
membrane between the ulna and radius and congenital
dislocation of the radial head were present (Fig. 5b).
Discussion
Previous reports show that the proportion of OI type V
patients may vary from 5 to 10% [10, 39]. According to
our results, out of 337 OI patients in the UT OI biobank,
less than 2% suffered from OI type V (five individuals).
Interestingly, in a cohort of Palestinian OI patients, there
were no carriers of the IFITM5 pathogenic variants, as
well as among our Estonian OI population [40]. We do
Fig. 4 Patient 4. a Genealogical tree of patient 4 (family 3). b Radiological features of patient 4
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not have evidence to assume, that such differences might
come from distinctions in the population genetics of dif-
ferent ethnic groups. But rather, the difference may be due
to differences in population size and recruitment of pa-
tients. We were also surprised to find a relatively higher
number of type V patients among Ukrainian OI cohort as
compared to our Vietnamese OI population, as sample
sizes and methods of patient recruitment were comparable.
Both the de novo and familial nature of the IFITM5
pathogenic variant was observed among our patients. In re-
lation to previously published data, we could assume that
the peak of the disease severity passes after puberty, and it
does not affect reproduction in OI type V patients [25, 28,
41]. However, similarly to collagen-related OI, the majority
of cases appear due to de novo pathogenic variants [42].
Both de novo and familial cases of type V showed a his-
tory of callus formation. As previous works have shown,
the majority of patients had HPC [42]. Because of this,
some patients may suffer from a series of misdiagnoses,
which precede a proper diagnosis. For example, patient 1
from our current study was previously diagnosed with
pseudo osteosarcoma due to extremely large HPC. Histo-
logical analysis has shown the presence of a mesh-like
lamellation pattern typical for HPC in OI V [25]. The HPC
in patient 1 represents the typical sign of OI V HPC, like
primitive woven bone with inflammation, hypercellular tra-
beculae, and small cartilaginous islands [26].
Intriguing results were provided by study of Liu et al.,
which has shown that the typical OI type V pathogenic
variant c.-14C > T in the IFITM5 gene promoted apop-
tosis in osteosarcoma cells, inhibited tumor invasion,
and promoted osteogenic differentiation [43]. However,
the exact mechanism is not yet known, interconnections
of osteosarcoma and OI type V in the form of a
MALEP-IFITM5 look encouraging for the management
of both diseases. Thus, patients with extreme cases of
HPC might be of interest.
Calcification of interosseous membrane was previously
detected in all OI type V patients older than age 4 [25,
44]. Similarly, to described Chinese OI patients, we do
not have any evidence of interosseous membrane calcifi-
cation in patient 4 and 5, who are 7 and 5 years old,
respectively.
In addition to patterns of unusual mineralization, our pa-
tients suffered from ordinary OI symptoms, like bone fragil-
ity, recurrent fractures, skeletal deformations, hearing loss,
joint laxity, teeth abnormalities, and bluish and grayish col-
ored sclera. To our knowledge, hearing loss was identified
in only one patient with OI type V [30]. Whereas, teeth ab-
normalities seemed to be more common. In the study of
Kim et al., teeth abnormalities relevant to OI type V pheno-
type were identified in 11/16 patients [45].
All of these characteristics might be caused by the al-
tered effect of mutated MALEP-IFITM5 protein on col-
lagen type I, as decreases in collagen expression were
previously identified in OI type V primary osteoblast cul-
tures and transgenic mouse models of OI type V [35,
46]. Thus, type I and IV mimicking symptoms might be
Fig. 5 Patient 5. a Genealogical tree of patient 5 (family 4). b Radiological features of patient 5
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connected to the presence of a quantitative collagen defect
in patients with OI type V. Whereas, the formation of
enormous bone callus and interosseous membrane calcifi-
cation might be caused by the effect of mutated MALEP-
IFITM5 on the process of increased mineralization in the
bone tissue.
Genetic testing ruled out misdiagnoses and confirmed
OI type V in patient 1. It helped to build up an appropri-
ate strategy for pharmacological and surgical treatment.
Similarly, in the rest of revealed cases (patients 2–5),
where classical OI was suspected, and treatment strategy
was updated. More cautious treatment approach is
needed to exclude risks and reduce potential complica-
tions, proceeding from the molecular defect of OI type
V. Moreover, results can be further used to provide fam-
ily planning counseling for these families and support
cost-effective and rapid genetic diagnosis of affected
family members in following generations.
Phenotype severity varied between patients in both OI
type V symptoms and classical OI features. The number
of fractures was different. As well as in other OI types,
the occurrence of fractures seemed to decrease after pu-
berty. However, growth retardation increased with age
and seemed to correlate with phenotype severity. The
phenotypical variation of OI type V has led us to the
conclusion that despite the OI causing effect, the pres-
ence of a pathogenic variant in the IFITM5 gene does
not shape phenotype in its full guise. Additional modify-
ing factors are not less important than the presence of
the IFITM5 pathogenic variant itself and are yet to be
discovered. A deep phenotyping description of OI type
V patients with different phenotype severity and the col-
lection of their genetic material is required for the fur-
ther investigation and understanding of OI type V.
Conclusions
We have investigated the presence of the OI type V c.-
14C >T 5′UTR IFITM5 pathogenic variant in a cohort of
OI patients negative for collagen I pathogenic variants with
and without symptoms of OI type V. We have identified
five individuals with OI type V from Ukrainian and Viet-
namese origin with various phenotype severity. Patient 4
had no visible features of OI type V, whereas patient 1 had
an extreme case of hyperplastic callus formation. Data from
our patients supports the presence of classical OI features
(hearing loss, bluish and grayish sclera, joint laxity, teeth
abnormalities) in OI type V in addition to typical OI type V
features such as abnormal mineralization. Due to high vari-
ation in clinical symptoms, we suggest the testing of
IFITM5 gene pathogenic variants in patients who lack OI
type V features. Identifying what pathogenic variants cause
OI is important for both doctors and patients, as it sup-
ports the organization of a proper treatment plan and fol-
low ups for patient and helps for responsible family
planning. Further investigations into the additional pheno-
type modifying factors and influence of MALEP-IFITM5
on osteogenesis should shed light on this rare and mysteri-
ous OI type.
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